No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home FINTECH

mAbxience and OncoPrecision Announce Manufacturing and Investment Agreement for OncoPrecision’s ADC Candidate ONC001

Cisionby Cision
November 18, 2026
Reading Time: 2 mins read
in FINTECH, IBERIA
Share on FacebookShare on Twitter

MADRID, Nov. 18, 2026 /PRNewswire/ — mAbxience, a wholly owned company of Fresenius SE & Co. KGaA, and OncoPrecision, a biotechnology company pioneering first-in-class precision therapies for hard-to-treat cancers through the integration of patient-derived biology and AI, headquartered in New York City; today announced an investment, development and manufacturing agreement for ONC001, OncoPrecision’s lead antibody-drug conjugate (ADC) candidate.

Under the terms of the agreement, mAbxience will be responsible for the development program of the antibody moiety of ONC001, covering activities from Cell Line Development (CLD) through process and analytical development, as well as the manufacture of GMP-grade material to support the program’s planned Phase I clinical trial.

ONC001 is a first-in-class CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages, with lead indications in monocytic acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) — aggressive blood cancers with few effective options and a median survival measured in months. ONC001 was first publicly disclosed in an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting and is advancing towards first-in-human studies.  

As part of the agreement, mAbxience will contribute with its scientific expertise, industrial capabilities, and Smart CoGs approach with its extensive experience in antibody development by supporting the program through the manufacture of the first GMP batch for clinical use. mAbxience has made a strategic investment in OncoPrecision and Jurgen Van Broeck, Chief Executive Officer of mAbxience, will join OncoPrecision’s Board of Directors as an Observer. Financial terms of the investment remain confidential. José Ramón Millán, Global Portfolio, CDMO & Partnering Director at mAbxience, said: “We are excited to partner with OncoPrecision on the development of ONC001, a promising ADC candidate that exemplifies the innovation emerging in oncology today. By bringing together our capabilities and long-term commitment, we aim to accelerate ONC001’s path to the clinic while creating sustainable value for both companies.“

Jurgen Van Broeck, Chief Executive Officer of mAbxience , said: “I’m pleased to support OncoPrecision through this partnership and as a Board Observer as they advance ONC001 towards Phase I studies and continue to make progress with their first-in-class pipeline.”

Tarek Ali Zaki, Co-Founder and Chief Executive Officer of OncoPrecision, said: “We’re thrilled to partner with mAbxience to accelerate ONC001’s path to the clinic through their world-class manufacturing capabilities and regulatory expertise. Bringing a fully-integrated biopharmaceutical partner with a shared vision of delivering meaningful medicines to patients marks an important step towards our company’s next stage.”

By combining OncoPrecision’s first-in-class candidate developed with its translational patient-derived discovery platform with mAbxience’s proven expertise in antibody development, process development, technology transfer, and GMP manufacturing, the two companies aim to accelerate the advancement of ONC001 toward first-in-human studies.

Cision View original content:https://www.prnewswire.co.uk/news-releases/mabxience-and-oncoprecision-announce-manufacturing-and-investment-agreement-for-oncoprecisions-adc-candidate-onc001-302943693.html

Read the orginal article: undefined

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

IBERIA

Woolpert Expands Global Data Center Practice with Acquisition of B-Global Tech

November 17, 2026
Revolut’s Italian branch in judicial administration for poor aml
FINTECH

Revolut’s Italian branch in judicial administration for poor aml

November 17, 2026
Italy’s angels & incubators and venture capital weekly roundup. News from Mosaico, Revolv Space, United Ventures, OpenOcean, Connect Ventures, Primo Capital, CDP, Sole Ventures, and more
FINTECH

Italy’s angels & incubators and venture capital weekly roundup. News from Mosaico, Revolv Space, United Ventures, OpenOcean, Connect Ventures, Primo Capital, CDP, Sole Ventures, and more

November 17, 2026

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsors

Premium

Private equity: 476 deals in Italy in the first nine months of 2026 and over €25 billion of stakes changing hands. The BeBeez report

Private equity: 476 deals in Italy in the first nine months of 2026 and over €25 billion of stakes changing hands. The BeBeez report

October 19, 2026

Western Balkans attract 50 billion euros for the Croatian data centre and 3.2 billion for Montenegro – Kinstellar report

September 29, 2026
The energy transition is now an asset class for private markets

The energy transition is now an asset class for private markets

June 25, 2026
The AI halves the time for creating value – FTI Consulting Private Equity Value Creation Index 2026

The AI halves the time for creating value – FTI Consulting Private Equity Value Creation Index 2026

June 10, 2026

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart